Level C· Early human research exploring benefitsProspective StudyPubMed

Purification of adipose tissue mesenchymal stem cells and differentiation toward hepatic-like cells.

Banas A.

Prospective Study on Face & Skin, published in Methods Mol Biol (2012) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Methods Mol Biol (2012)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
22167640
DOI
10.1007/978-1-61779-468-1_6
Citations
24

Abstract (original English)

There is a great interest in the development of functional hepatocytes in vitro from different types of stem cells. Multipotential mesenchymal stem cells (MSC) compose a great source for stem cell based therapy, especially, because they can be obtain from patients own tissues, sidestepping immunocompatibility and ethical issues. Among MSCs from different sources, adipose-tissue-derived mesenchymal stem cells (AT-MSCs) are very promising because of their high accessibility, proliferation ability, potentiality, and immunocompatibility.AT-MSCs can be easily isolated from stroma vascular fraction (SVF) of adipose tissue. They represent a heterogeneous population of cells. The precise AT-MSCs's marker profile has not been defined yet; therefore, it is still not obvious how to purify these heterogeneous fraction of cells. We postulate that one of the markers defining MSC provenance is CD105 (endoglin).Therefore, we have sorted CD105(+) fraction of AT-MSCs, expanded them, and differentiated toward hepatic-like cells. In order to check their potentiality, we have firstly differentiated sorted CD105(+) AT-MSCs toward mesoderm lineages, using commercialized protocols.We have shown here, that pure CD105(+) AT-MSCs fraction revealed higher homogeneity and differentiation potential toward adipogenic, osteogenic, and chondrogenic lineages and highly inducible into the hepatogenic lineage.Gen

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Adipose TissueAntigens, CDBlotting, WesternCell Culture TechniquesCell DifferentiationCell SeparationChondrogenesisDNA PrimersEndoglinHepatocytes

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research